Clinical Trial Update: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) [Phase 4]

View source ↗

Summary

A Phase 4 longitudinal study evaluating eltrombopag over two years in adults with chronic immune thrombocytopenia who had prior treatment; the trial is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 4 | Status: COMPLETED | Results posted: 2015-03-12